GlassScriptPhysician profile
Michael James Snyder
NPI 1457389132
$9,367.00
in general payments reported to CMS, 2019-2025
48 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,851 · 2020: $741 · 2021: $375 · 2022: $677 · 2023: $1,347 · 2024: $692 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.39 |
| Education | $116.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $2,783.15 | 2019 | |
| Glaxosmithkline, LLC. | $1,486.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $727.54 | 2020-2025 | Glassia, Eohilia, Cuvitru |
| Olympus Corporation of The Americas | $590.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.01 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $314.77 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $292.53 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $279.98 | 2019-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $232.05 | 2019-2025 | |
| Grifols USA, LLC | $213.94 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals LP | $209.26 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Pfizer INC. | $181.25 | 2019-2025 | |
| Mylan Specialty L.P. | $171.61 | 2019-2024 | Yupelri |
| Abiomed | $144.36 | 2019 | |
| Edwards Lifesciences Corporation | $126.46 | 2019 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.85 | 2019-2023 | Xarelto |
| Janssen Biotech, INC. | $67.28 | 2023-2025 | Tremfya, Stelara |
| Jazz Pharmaceuticals INC. | $61.64 | 2022-2025 | |
| Philips North America LLC | $60.86 | 2019-2023 | |
| Amgen INC. | $59.86 | 2023-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $58.45 | 2019-2020 | |
| Electromed, INC. | $48.12 | 2021-2025 | Smartvest |
| Harmony Biosciences LLC | $48.01 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $41.02 | 2023 | Sunosi |
| Advanced Respiratory, INC | $40.68 | 2020 | |
| Paratek Pharmaceuticals, INC. | $39.03 | 2019-2022 | |
| Csl Behring | $36.42 | 2022-2025 | Hizentra |
| Lungpacer Medical USA INC | $31.09 | 2025 | Aeropace Neurostimulation Console |
| Gilead Sciences, INC. | $27.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.59 | 2019-2020 | |
| Octapharma USA, INC. | $24.04 | 2024 | Cutaquig |
| United Therapeutics Corporation | $23.77 | 2023 | Tyvaso |
| Shionogi INC | $23.40 | 2024 | Fetroja |
| Idorsia Pharmaceuticals US INC | $18.56 | 2023 | Quviviq |
| C. R. Bard, INC. & Subsidiaries | $18.47 | 2023 | Arctic Sun 5000 |
| Azurity Pharmaceuticals, INC. | $17.90 | 2024 | Horizant |
| Ekos Corporation | $17.64 | 2019 | |
| Genentech, INC. | $17.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.19 | 2019 | |
| Shire North American Group INC | $17.12 | 2019 | |
| Inogen, INC. | $16.84 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Lilly USA, LLC | $16.68 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $14.84 | 2021 | |
| Genentech USA, INC. | $14.15 | 2019 | |
| Verona Pharma, INC. | $14.12 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $13.98 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Avadel Cns Pharmaceuticals, LLC | $13.78 | 2025 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.